Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.61 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1409830 | 0.87 | KDM4E (0.64) | KDM4EALDH1A1HPGDPDCD1CD274 | |
| SCHEMBL29840068 | 0.85 | GAA (0.67) | KDM4EALDH1A1HPGDPOLBSMN1; SMN2 | |
| SCHEMBL894741 | 0.85 | SIRT2 (0.70) | KDM4EALDH1A1HPGDPDCD1CD274 | |
| SCHEMBL45762 | 0.85 | KDM4E (0.60) | KDM4EALDH1A1HPGDPDCD1CD274 | |
| SCHEMBL3928666 | 0.85 | GAA (0.67) | KDM4EALDH1A1HPGDPOLBSMN1; SMN2 | |
| SCHEMBL30139987 | 0.85 | KDM4E (0.60) | KDM4EALDH1A1HPGDPDCD1CD274 | |
| SCHEMBL6326283 | 0.84 | KMT2A (0.62) | KDM4EALDH1A1HPGDPOLBLMNA | |
| SCHEMBL10424663 | 0.84 | SIRT2 (0.62) | KDM4EALDH1A1HPGDSIRT2MAPT | |
| SCHEMBL9921482 | 0.84 | KDM4E (0.56) | KDM4EALDH1A1HPGDPDCD1CD274 | |
| SCHEMBL175535 | 0.84 | KDM4E (0.56) | KDM4EALDH1A1HPGDPDCD1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3843845-B1 | INHIBITION OF PROTEIN KINASES TO TREAT FRIEDREICH ATAXIA | UNIV MASSACHUSETTS (US) | 2026-03-11 | — | — | EP | claimed |
| US-12281308-B2 | Inhibition of protein kinases to treat Friedreich ataxia | UNIVERSITY OF MASSACHUSETTS (US) | 2025-04-22 | — | — | US | claimed |
| US-20210292766-A1 | Inhibition of Protein Kinases to Treat Friedreich Ataxia | UNIVERSITY OF MASSACHUSETTS | 2021-09-23 | — | — | US | claimed |
| EP-3843845-A1 | INHIBITION OF PROTEIN KINASES TO TREAT FRIEDREICH ATAXIA | University Of Massachusetts (US) | 2021-07-07 | — | — | EP | claimed |
| WO-2020047229-A1 | INHIBITION OF PROTEIN KINASES TO TREAT FRIEDREICH ATAXIA | UNIVERSITY OF MASSACHUSETTS (US) | 2020-03-05 | — | — | WO | claimed |
| US-5872115-A | COMPOUNDS FOR TREATMENT OF HYPERCHOLESTEROLEMIA, ISCHEMIC HEART DISEASE, CEREBROVASCULAR DISEASE OR ATHEROSCLEROSIS | GRELAN PHARMACEUTICAL CO. LTD. (JP) | 1999-02-16 | — | — | US | claimed |
| EP-0742208-A1 | 2-Ureido-benzamide derivatives | GRELAN PHARMACEUTICAL CO., LTD. (JP) | 1996-11-13 | — | — | EP | claimed |
| JP-58067671-A | — | — | None | — | — | JP | disclosed |
| JP-59181257-A | — | — | None | — | — | JP | disclosed |
| JP-59175467-A | — | — | None | — | — | JP | disclosed |
| EP-3843845-B1 | INHIBITION OF PROTEIN KINASES TO TREAT FRIEDREICH ATAXIA | UNIV MASSACHUSETTS (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20250304576-A1 | IKK INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2025-10-02 | — | — | US | disclosed |
| US-12281308-B2 | Inhibition of protein kinases to treat Friedreich ataxia | UNIVERSITY OF MASSACHUSETTS (US) | 2025-04-22 | — | — | US | disclosed |
| US-5872115-A | COMPOUNDS FOR TREATMENT OF HYPERCHOLESTEROLEMIA, ISCHEMIC HEART DISEASE, CEREBROVASCULAR DISEASE OR ATHEROSCLEROSIS | GRELAN PHARMACEUTICAL CO. LTD. (JP) | 1999-02-16 | — | — | US | disclosed |
| EP-0742208-A1 | 2-Ureido-benzamide derivatives | GRELAN PHARMACEUTICAL CO., LTD. (JP) | 1996-11-13 | — | — | EP | disclosed |
| EP-0742208-A1 | 2-Ureido-benzamide derivatives | GRELAN PHARMACEUTICAL CO., LTD. (JP) | 1996-11-13 | — | — | EP | disclosed |
| EP-0742208-A1 | 2-Ureido-benzamide derivatives | GRELAN PHARMACEUTICAL CO., LTD. (JP) | 1996-11-13 | — | — | EP | disclosed |
| JP-S59181257-A | UREIDOBENZAMIDE DERIVATIVE | CHUGAI PHARMACEUT CO LTD | 1984-10-15 | — | — | JP | disclosed |
| JP-S59175467-A | UREIDOBENZAMIDE DERIVATIVE | CHUGAI PHARMACEUT CO LTD | 1984-10-04 | — | — | JP | disclosed |
| JP-S5867671-A | UREIDOBENZAMIDE DERIVATIVE | CHUGAI PHARMACEUT CO LTD | 1983-04-22 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304576-A1 | IKK INHIBITORS | NFKBIA, IKBKE, IKBKB | KDM4E 1442/4885ALDH1A1 4083/4885HPGD 2408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.